Oncotrace RGCC is used to identify a primary tumour in a patient and to provide guidance about disease progression and future prognosis.

During the test, a sample of blood is analysed to identify the presence and concentration of circulating tumour cells (CTCs) and their concentration. This test provides information about the presence of CTCs, their concentration and their specific type (immunophenotype).

The results of the test enable clinicians to identify the origin of a tumour where this is unknown and to provide information on the development of cancer and the prognosis.